Abstract: In part, the present invention is directed to coordination complexes comprising a therapeutic agent. In one aspect, the subject compositions comprise a platinum metal center and a covalently attached therapeutic agent.

Abstract: The invention provides methods useful for the treatment of tumors and other diseases. The methods of the invention involve the administration of a composition containing human vascular endothelial growth factor (VEGF) and radiolabeled human transferrin to a host having a tumor.

Abstract: The invention provides a composition containing two conjugates; the first conjugate containing human vascular endothelial growth factor (VEGF) and radiolabeled human transferrin and the second conjugate containing human epidermal growth factor (EGF) and radiolabeled human transferrin. The composition is useful for the treatment of tumors and other diseases.

Abstract: The invention provides a composition containing human vascular endothelial growth factor (VEGF), radiolabeled human transferrin and human epidermal growth factor (EGF). The composition is useful for the diagnosis, imaging and treatment of tumors and other diseases.

Abstract: The invention provides compositions containing a ligand such as human epidermal growth factor (EGF) or human vascular endothelial growth factor (VEGF), an anti-tumor agent and a human transferrin ligand. The compositions are useful for the delivery of anti-tumor agents to a host having a tumor.

Abstract: The invention provides compositions containing at least one ligand such as human epidermal growth factor (EGF) or human vascular endothelial growth factor (VEGF), a nucleic acid and a human transferrin ligand. The compositions are useful for the multi-targeted delivery of nucleic acids to cells and tissues.

Abstract: The invention provides methods useful for the treatment of tumors and other diseases. The methods of the invention involve the administration of a composition containing two conjugates; the first conjugate containing human vascular endothelial growth factor (VEGF) and radiolabeled human transferrin and the second conjugate containing human epidermal growth factor (EGF) and radiolabeled human transferrin to a host having a tumor.

Abstract: The invention provides a composition containing human vascular endothelial growth factor (VEGF) and radiolabeled human transferrin. The composition is useful for the treatment of tumors and other diseases.

Abstract: The invention provides a composition containing human epidermal growth factor (EGF) and radiolabeled human transferrin. The composition is useful for the treatment of tumors and other diseases.

Abstract: The invention comprises a preparation of X-S-Cys-X, moiety, BRAUNMYCIN Î>>, where X maybe naturally linked peptide or glycan residues essential for iron-reductase activity, as well as methods of obtaining preparation from an iron-nitriloacetic acid iron binding jaw, BRAUNMYCIN8567, a component of a batch affinity column; and any interpretation derived from this outcome, like, but not limited to, detection of resistance, to iron-containing antibiotics, in DNA synthesizing cells.

Abstract: Enantiomer-pure compounds of general formulas VIIa and VIIb 1

Abstract: Disclosed are peptide aggregates that include assembling peptides optionally linked to metal binding moieties and/or target binding moieties. Also disclosed are methods of using such peptide aggregates for magnetic resonance imaging.

Abstract: Provided are a method for easily detecting phosphorylated peptides, namely, proteins, in samples derived from living organisms or the like, a method for selectively adsorbing the phosphorylated peptides, and compounds that are highly coordinated to the phosphorylated peptides and usable in the methods.

Abstract: A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of: (i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound peptides; and (ii) contacting the peptides isolated form step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides; wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease. Peptides identified using the screening method may be used to treat AD, type II diabetes, Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE).

Abstract: The present invention relates to:

Abstract: Zinc finger proteins of the Cys2His2 type represent a class of malleable DNA binding proteins which may be selected to bind diverse sequences. Typically, zinc finger proteins containing three zinc finger domains, like the murine transcription factor Zif268 and the human transcription factor Sp1, bind nine contiguous base pairs (bp). To create a class of proteins which would be generally applicable to target unique sites within complex genomes, the present invention provides a polypeptide linker that fuses two three-finger proteins. Two six-fingered proteins were created and demonstrated to bind 18 contiguous bp of DNA in a sequence specific fashion. Expression of these proteins as fusions to activation or repression domains allows transcription to be specifically up or down modulated within cells. Polydactyl zinc finger proteins are broadly applicable as genome-specific transcriptional switches in gene therapy strategies and the development of novel transgenic plants and animals.

Abstract: Linear extended polymeric paramagnetic chelates for use as MRI contrast agents are synthesized by conjugating DTPA chelator moieties to higher than 90% of the monomer residues of the polyamino acid backbone chain. The resulting polymer can be labeled with Gd, since each chelator moiety holds a Gd ion, and the resulting conformation is of an unfolded, extended linear type, capable of entering small pores and moving around obstacles in the extracellular space of tissues. The efficient production of these extended polymers is critical for the application of such contrast agents to medical imaging. One such agent is a reptating polymer containing technetium-99.

Abstract: A method for obtaining a cobalt-apoferritin complex according to the present invention includes: the step a) of preparing a solution including a Co2+ ion, a protein, a pH buffer agent and a Co2+ associating agent; and the step b) of adding an oxidizing agent to the solution and thereby making the protein contain a fine particle including cobalt.

Abstract: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anticancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the conjugate. The targeting protein is preferably transferrin.

Abstract: The invention discloses compounds and compositions for dual phototherapy and combined therapy and diagnosis of tumors and other lesions. The compounds have a Dye that, when photoactivated, operates via Type I and/or Type II mechanisms. Other Dye or azide components may operate by the same or different mechanisms. Selection of particular components in a compound, and formulation of the compound(s) in a composition permit different activation wavelengths to be used for different therapies. A targeting moiety may be added to the compound or composition so that the Dye locates at a particular site, such as a hormone-sensitive tumor, for diagnosis and/or treatment. The compounds and compositions may be incorporated within liposomes.

Abstract: This invention provides a protein which exhibits metal ion binding activity. The protein can be readily extracted from the pacific oyster, Crassostrea gigas and can be formulated into bioremediation compositions, foodstuffs, nutraceuticals, and the like.

Abstract: Disclosed are compositions, useful for stimulating hair growth in warm-blooded animals in need thereof, that combine at least one peptide copper complex and Minoxidil. The disclosed compositions may be formulated so as to be suitable for topical application or for intradermal injection to areas of skin in need thereof. Also disclosed are methods for stimulating hair growth to thereby treat various hair growth afflictions, such as androgenetic alopecia, alopecia areata, or secondary alopecia. Generally, the disclosed methods comprise applying, topically or via intradermal injection, a stimulatory effective amount of a disclosed composition to an area of a patient's skin in need thereof. In one embodiment, the disclosed method employs such application in a continued and periodic fashion to arrest and/or reverse androgenetic alopecia.

Abstract: The present invention provides artificial endonucleases and methods to prepare and use those endonucleases.

Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.

Abstract: This invention provides modified biopolymers comprising biopolymers attached to at least one non-proteinaceous catalyst capable of dismutating superoxide in the biological system or precursor ligand thereof. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.

Abstract: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents.

Abstract: Nanoparticulate composites and dispersion thereof using novel polymeric ligand compounds, in certain embodiments in conjunction with pyridinyl moieties coupling the nanoparticulate and ligand.

Abstract: An anti-tumor pharmaceutical composition comprises the conjugation of Canavalia ensiformis-extracted protein with metal ions to form a metalloprotein complex for inhibiting the growth of tumor with enhanced activity and stability, but without toxicity.

Abstract: The present invention provides for an improved method of preparing fetuin by using a chelating agent to remove inorganic ions, such as zinc, calcium, and barium, from fetuin. Then, reloading the “naked” fetuin with Zinc Acetate to form a product that is mainly Fetuin-Zinc. This improved method of preparing Fetuin-Zinc or supercharged zinc fetuin increases the effectiveness of inducing apoptosis in cancer cells by three to four times.

Abstract: A competitive immunoassay, dye and method for rapidly detecting the presence of one or more target ligands within a fluid sample suspected of containing such ligand or ligands. The immunoassay comprises a protein-binding membrane, a first absorbent pad, a second absorbent pad, and a third absorbent pad. The protein-binding membrane has at least two regions of antibodies bound thereto for detecting dissimilar ligands. The second absorbent pad has formed therein a colloidal gold tracer having one, and preferably two or more ligand analog protein complexes adhering thereto. To utilize the system, the immunoassay strip is placed within a fluid sample. To the extent the target ligand is absent, a visual indicator will be provided signaling such absence. To the extent the target ligand is present at or above a threshold level, no such visual signal will be produced.

Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.

Abstract: The present invention relates to a nanoparticle comprising a specific binding reactant, said nanoparticle being useful for determining an analyte to which analyte or complex comprising said analyte said binding reactant is specific. Characteristic for the nanoparticle is that the diameter of said nanoparticle is less than 200 nm, said nanoparticle is coated with multiple said specific binding reactants to the extent that the affinity constant of said nanoparticle towards said analyte essentially exceeds that of free said binding reactant towards said analyte and/or the association rate constant between said nanoparticle and said analyte essentially exceeds the association rate constant between free said binding reactant and said analyte; and said nanoparticle comprises a detectable feature. The invention also relates to biochemical assays using said nanoparticle.

Abstract: A biochemical labeling material and manufacturing method thereof. The manufacturing method provides a plurality of nanoparticles, bonding the nanoparticles to template molecules by molecular imprinting, polymerizing the nanoparticles to form a matrix with uniformly-distributed template molecules, finally removing the template molecules from the matrix to reveal a detection group of the matrix, leaving a cavity with specific area.

Abstract: This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is H-T-F-S-G-V-A-S-V-E and correlates to amino acid no. 300-309 of fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LD50 of 0.3-0.4 &mgr;M, while the LD50 for zinc-charged fetuin is 3-10 &mgr;M.

Abstract: Novel therapeutic lipid constructs comprising a lipid construct, an anti-cell surface targeting agent, and a radiotherapeutic metal ion are disclosed.

Abstract: In one aspect, the invention provides covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins. In some embodiments, the covalent conjugates comprise artelinate and holotransferrin. In another aspect, the invention provides methods for administering the covalent conjugates of the invention to treat cancer and infections by pathogens that bind iron-carrying proteins.

Abstract: Protein polymers coated with a metal are provided. New methods are described for the preparation of tubulin-based microtubules such that they may be coated, by an electroless plating method, with gold particles of <20 nm in diameter without prior reaction with noble metal catalysts. The gold particle deposition can occur in suspension or on microtubules lying on a surface. Gold enhancement of the gold-particle coating and annealing results in ohmic conductance that is within a factor of ten of the resistivity of bulk gold. These methods are likely to be applicable to other protein polymers.

Abstract: The invention pertains to silver halide emulsions for photographic uses. The emulsions contain a nucleation peptiser, said nucleation peptiser being a polypeptide comprising: at least one region A comprising up to 100 amino acids, either consisting of (i) at least two silver-binding amino acids and up to 98 amino acids between said two silver-binding amino acids, or consisting of (ii) a stretch of from 9 to 100 amino acids having a polarity corresponding to an average transfer free energy &dgr;F equal to or higher than +1.0 kcal/mol, and at least one region B (separated from region A) comprising at least 50 amino acids and having a polarity corresponding to an average transfer free energy equal to or lower than −1.0 kcal/mol and not containing methionine residues. The emulsion may also contain a growth peptiser having similar characteristics as the nucleation peptiser, but having a longer A region and a greater overall length.

Abstract: The object of the present invention is to provide Mms 16, a protein specific to a magnetic particle membrane derived from a magnetic bacterium (Magnetospirillum sp.) AMB-1, DNA which encodes the protein, and a sandwich immunoassay method and a pharmaceutical composition, etc., using the same. Mms 16, a novel protein specific to a bacterial magnetic particle membrane, was identified by: fractionating cell homogenate of magnetic bacteria into 3 fractions of cell membranes, magnetic particle membranes, and cytoplasms, and by comparing the SDS-PAGE profiles of each protein. Further, an amino acid sequence of the protein or a base sequence of a gene that encodes the protein was determined and it was confirmed that the protein exhibited GTPase activity.

Abstract: The present invention provides a compound for chelating a metal or a metal complex, characterized in that it consists of a bis-dithiocarbamate structure (F) having the formula below: 1

Abstract: Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.

Abstract: The invention concerns a process for the production of metal chelate-labelled peptide antigens, peptides obtainable by this process and their use in an immunological method of detection.

Abstract: A novel encoding system, compositions for use therein and methods for determining the source, location and/or identity of a particular item or component of interest is provided. In particular, the present invention utilizes a collection of one or more sizes of populations of semiconductor nanocrystals having characteristic spectral emissions, to “track” the source or location of an item of interest or to identify a particular item of interest. The semiconductor nanocrystals used in the inventive compositions can be selected to emit a desired wavelength to produce a characteristic spectral emission in narrow spectral widths, and with a symmetric, nearly Gaussian line shape, by changing the composition and size of the semiconductor nanocrystal. Additionally, the intensity of the emission at a particular characteristic wavelength can also be varied, thus enabling the use of binary or higher order encoding schemes.

Abstract: This invention provides therapeutic and diagnostic agent delivery vehicles, including viral vectors, that are complexed to a targeting moiety by coordinate covalent linkages mediated by a transition metal ion. The complex is typically formed with a transition metal ion that is in a kinetically labile oxidation state; after the complex is formed, the oxidation state of the transition metal ion is changed to one that renders the complex kinetically stable. The use of a coordinate covalent linkage to attach the targeting moiety to the delivery vehicle provides advantages such as the ability to readily attach a different targeting moiety to a delivery vehicle without modifying the delivery vehicle itself. This flexibility is achieved without sacrificing stability of the complex.

Abstract: The present invention relates to mutations in the gene coding for ferroportin 1 associated with hereditary haemochromatosis and methods for the diagnosis of hereditary haemochromatosis based on the identification of such mutations.

Abstract: The present invention is directed to novel compositions and methods utilizing nanoparticles comprising protein cages and cores.

Abstract: The present invention provides a novel metal complex useful for a reagent for determining the amino acid sequence of protein or peptide, and a method of using it for determining the amino acid sequence of protein or peptide. The metal complex which has a functional group capable of forming a covalent bond with the amino group of the N-terminal amino acid residue of protein or peptide or with the carboxyl group of the C-terminal amino acid residue of protein or peptide. In general, the functional group is in the ligand of the complex.

Abstract: A biocompatible molecule includes a polypeptide containing lysine residues and either gluatmic acid or aspartic acid residues, less than 90% of the lysine residues being substituted with a group derived from a steric hindrance molecule, the substituted polypeptide having a conformation with a length that is 5 to 500 times its average diameter.

Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

Abstract: Methods are described for conjugating radioiodinated peptides or carbohydrate structures to proteins with improved yields and qualities of conjugates. In one method, specially designed radioiodinated bifunctional peptides containing nonmetabolizable amide bonds are coupled to antibodies. In a second method, radioiodinated nonmetabolizable bifunctional peptides, which also contain aminopolycarboxylates, are coupled to antibodies. In a third method, radioiodinated bifunctional aminopolycarboxylates are coupled to antibodies. In a fourth method, a hydrazide-appended antibody is coupled to a radioiodinated carbohydrate or a thiolated antibody is coupled to a hydrazide-appended and radioiodinated carbohydrate. In a fifth method a monoderivatized cyanuric chloride is used to conjugate thiolated antibody. Radioiodinated residualizing antibody conjugates made by these methods are particularly stable in vivo and are suitable for radioimmunodetection and radioimmunotherapy.